Minimal residual disease (MRD) is an important prognostic factor for evaluating a deeper treatment response in patients with multiple myeloma (MM). We evaluated the clinical utility of next-generation flow (NGF)-based MRD assessment in a heterogeneous MM patient population.

中文翻译：

---

多发性骨髓瘤患者下一代基于流量的最小残留疾病评估的临床效用。

微小残留病灶 (MRD) 是评估多发性骨髓瘤 (MM) 患者更深层次治疗反应的重要预后因素。我们评估了基于下一代流量 (NGF) 的 MRD 评估在异质 MM 患者群体中的临床效用。